Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol May Be An Acquisition Target Following Entry Of Plavix Generics

Executive Summary

The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target

Related Content

Pfizer/Sanofi speculation
Sanofi Tries To Quash Bristol Rumors; M&A Efforts Center On Biotech, Japan
Bristol investigation expands
Bristol Is Not For Sale, CEO Says; Plavix Woes Partly Offset By Other Products
Pfizer May Be Regaining Appetite For Large M&A; Is Bristol On The Menu?
Pfizer Set For “Fundamental And Sustained” Change Under New CEO Kindler
What’s Old Is New Again: Bristol Cancer Plans Re-Emphasize Cytotoxics
Pharma M&A: An Unattractive But Inevitable Reality?
Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
Bristol $300 Mil. DoJ Settlement Includes Separation OF CEO/Chairman Roles



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts